# AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

> **NCT06665165** · PHASE1 · RECRUITING · sponsor: **Amylyx Pharmaceuticals Inc.** · enrollment: 48 (estimated)

## Conditions studied

- ALS

## Interventions

- **DRUG:** AMX0114
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06665165
- **Lead sponsor:** Amylyx Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2027-02
- **Final completion:** 2027-10
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06665165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06665165, "AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06665165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*